Don't MissASCO in 30: Immunotherapy controversy & less is just as good By Sharon Begley and Adam Feuerstein June 3, 2018 Reprints ASCO in 30: Immunotherapy controversy & less is just as good About the Authors Reprints Sharon Begley Senior Writer, Science and Discovery (1956-2021) Sharon covered science and discovery. @sxbegle Adam Feuerstein Senior Writer, Biotech Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast. [email protected] @adamfeuerstein
Don't Miss STAT Staff Introducing the 2023 STATUS List, the definitive accounting of leaders in the life sciences
Business Bob Herman and Casey Ross STAT Plus: Buyer’s remorse: How a Medicare Advantage business is strangling one of its first funders
A STAT Investigation Casey Ross and Bob Herman STAT Plus: Denied by AI: How Medicare Advantage plans use algorithms to cut off care for seniors in need
Special Report Jason Mast, Allison DeAngelis and Megan Molteni STAT Plus: CRISPR patent fight redux? A new battle is brewing among biotechs over next-gen gene-editing tools
